Use of Treponemal Screening Assay Strength of Signal to Avoid Unnecessary Confirmatory Testing
Our reverse syphilis testing algorithm consists of a treponemal IgG multiplex flow immunoassay (MFI) followed by both rapid plasma reagin titer and the Treponema pallidum particle agglutination (TPPA) test on specimens with a reactive MFI result. We report here the impact of a modified reverse algor...
Saved in:
| Published in: | Sexually transmitted diseases Vol. 43; no. 12; p. 737 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.12.2016
|
| Subjects: | |
| ISSN: | 1537-4521, 1537-4521 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Our reverse syphilis testing algorithm consists of a treponemal IgG multiplex flow immunoassay (MFI) followed by both rapid plasma reagin titer and the Treponema pallidum particle agglutination (TPPA) test on specimens with a reactive MFI result. We report here the impact of a modified reverse algorithm, in which the strength of signal of the MFI is used to avoid unnecessary TPPA testing.
The Bioplex syphilis IgG MFI was used as the syphilis screening assay, and specimens with equivocal (antibody index 0.9 or 1.0), or reactive (antibody index ≥ 1.1) results were further tested by rapid plasma reagin titer and TPPA test. We performed a retrospective, descriptive analysis of all specimens received for syphilis screening between January and May of 2014. A cost analysis was performed, taking into account labor and reagent expenses.
In our diverse patient population consisting of high-risk incarcerated persons, low-risk obstetrical/gynecological patients and high-risk miscellaneous clinic and inpatients, 430 (65%) of 665 MFI-positive specimens had antibody indices of 8 or greater. Greater than 99% of these specimens were reactive by the TPPA test. Avoiding TPPA testing of specimens with an MFI antibody index ≥8 would save over US $4800 annually in laboratory costs.
The TPPA testing is unnecessary on specimens with MFI antibody indices ≥8. This would substantially reduce the TPPA testing volume and also reduce laboratory expenses. |
|---|---|
| AbstractList | Our reverse syphilis testing algorithm consists of a treponemal IgG multiplex flow immunoassay (MFI) followed by both rapid plasma reagin titer and the Treponema pallidum particle agglutination (TPPA) test on specimens with a reactive MFI result. We report here the impact of a modified reverse algorithm, in which the strength of signal of the MFI is used to avoid unnecessary TPPA testing.
The Bioplex syphilis IgG MFI was used as the syphilis screening assay, and specimens with equivocal (antibody index 0.9 or 1.0), or reactive (antibody index ≥ 1.1) results were further tested by rapid plasma reagin titer and TPPA test. We performed a retrospective, descriptive analysis of all specimens received for syphilis screening between January and May of 2014. A cost analysis was performed, taking into account labor and reagent expenses.
In our diverse patient population consisting of high-risk incarcerated persons, low-risk obstetrical/gynecological patients and high-risk miscellaneous clinic and inpatients, 430 (65%) of 665 MFI-positive specimens had antibody indices of 8 or greater. Greater than 99% of these specimens were reactive by the TPPA test. Avoiding TPPA testing of specimens with an MFI antibody index ≥8 would save over US $4800 annually in laboratory costs.
The TPPA testing is unnecessary on specimens with MFI antibody indices ≥8. This would substantially reduce the TPPA testing volume and also reduce laboratory expenses. Our reverse syphilis testing algorithm consists of a treponemal IgG multiplex flow immunoassay (MFI) followed by both rapid plasma reagin titer and the Treponema pallidum particle agglutination (TPPA) test on specimens with a reactive MFI result. We report here the impact of a modified reverse algorithm, in which the strength of signal of the MFI is used to avoid unnecessary TPPA testing.BACKGROUNDOur reverse syphilis testing algorithm consists of a treponemal IgG multiplex flow immunoassay (MFI) followed by both rapid plasma reagin titer and the Treponema pallidum particle agglutination (TPPA) test on specimens with a reactive MFI result. We report here the impact of a modified reverse algorithm, in which the strength of signal of the MFI is used to avoid unnecessary TPPA testing.The Bioplex syphilis IgG MFI was used as the syphilis screening assay, and specimens with equivocal (antibody index 0.9 or 1.0), or reactive (antibody index ≥ 1.1) results were further tested by rapid plasma reagin titer and TPPA test. We performed a retrospective, descriptive analysis of all specimens received for syphilis screening between January and May of 2014. A cost analysis was performed, taking into account labor and reagent expenses.METHODSThe Bioplex syphilis IgG MFI was used as the syphilis screening assay, and specimens with equivocal (antibody index 0.9 or 1.0), or reactive (antibody index ≥ 1.1) results were further tested by rapid plasma reagin titer and TPPA test. We performed a retrospective, descriptive analysis of all specimens received for syphilis screening between January and May of 2014. A cost analysis was performed, taking into account labor and reagent expenses.In our diverse patient population consisting of high-risk incarcerated persons, low-risk obstetrical/gynecological patients and high-risk miscellaneous clinic and inpatients, 430 (65%) of 665 MFI-positive specimens had antibody indices of 8 or greater. Greater than 99% of these specimens were reactive by the TPPA test. Avoiding TPPA testing of specimens with an MFI antibody index ≥8 would save over US $4800 annually in laboratory costs.RESULTSIn our diverse patient population consisting of high-risk incarcerated persons, low-risk obstetrical/gynecological patients and high-risk miscellaneous clinic and inpatients, 430 (65%) of 665 MFI-positive specimens had antibody indices of 8 or greater. Greater than 99% of these specimens were reactive by the TPPA test. Avoiding TPPA testing of specimens with an MFI antibody index ≥8 would save over US $4800 annually in laboratory costs.The TPPA testing is unnecessary on specimens with MFI antibody indices ≥8. This would substantially reduce the TPPA testing volume and also reduce laboratory expenses.CONCLUSIONSThe TPPA testing is unnecessary on specimens with MFI antibody indices ≥8. This would substantially reduce the TPPA testing volume and also reduce laboratory expenses. |
| Author | Loeffelholz, Michael J Berry, Gregory J |
| Author_xml | – sequence: 1 givenname: Gregory J surname: Berry fullname: Berry, Gregory J organization: From the Department of Pathology, University of Texas Medical Branch, Galveston, TX – sequence: 2 givenname: Michael J surname: Loeffelholz fullname: Loeffelholz, Michael J |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27835625$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtLAzEQgINU7EP_gUiOXrbmsdnHsRSrQsFD26tLspnUld2kTXaF_nsjVugc5gEf3wwzRSPrLCB0T8mckjJ_cu1xTi5DsPQKTajgeZIKRkcX_RhNQ_gihKYFoTdozPKCi4yJCfrYBcDO4K2HQ_R3ssWb2gPYxu7xIgR5wpveg933n7_YptnbiPQOL75do_HOWqghYv6El86axneyd3HYQuij4hZdG9kGuDvXGdqtnrfL12T9_vK2XKyTWhCRJiUoQnXGS6q1KYAro1hdUqkKIw1wUefCZIwpwTShVBYqL3WaMq5JFjuSsxl6_PMevDsOcXfVNaGGtpUW3BAqWkQ3jZlH9OGMDqoDXR1808Xzq_-fsB8dEWbJ |
| CitedBy_id | crossref_primary_10_3138_jammi_2024_0027 crossref_primary_10_1016_j_clinbiochem_2018_09_013 crossref_primary_10_1128_JCM_01487_18 crossref_primary_10_1016_j_diagmicrobio_2020_115303 crossref_primary_10_1128_JCM_01165_17 crossref_primary_10_1111_jdv_16946 crossref_primary_10_1016_j_diagmicrobio_2024_116267 crossref_primary_10_1128_JCM_00215_18 crossref_primary_10_4103_ijstd_ijstd_115_24 crossref_primary_10_1093_ofid_ofae207 crossref_primary_10_1097_OLQ_0000000000001386 crossref_primary_10_1371_journal_pone_0204001 crossref_primary_10_15585_mmwr_rr7004a1 crossref_primary_10_1093_cid_ciaa307 crossref_primary_10_3389_fcimb_2025_1578060 crossref_primary_10_1097_OLQ_0000000000001621 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/olq.0000000000000524 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-4521 |
| ExternalDocumentID | 27835625 |
| Genre | Journal Article |
| GroupedDBID | --- -ET ..I .GJ .XZ .Z2 01R 0R~ 123 1CY 1J1 354 40H 4Q1 4Q2 4Q3 53G 5RE 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAUEB AAWTL AAXQO AAYEP AAZDW ABASU ABBHK ABBUW ABDIG ABHFT ABJNI ABPXF ABVCZ ABXSQ ABXVJ ABXYN ABZAD ABZZY ACCJW ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACLDA ACOAL ACPRK ACWDW ACWRI ACXJB ACXNZ ACZKN ADFPA ADGGA ADGHP ADHPY ADNKB ADULT AE3 AE6 AEBDS AEETU AENEX AEUPB AFBFQ AFDTB AFEXH AFFNX AFMBP AFNMH AFRAH AFSOK AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHVBC AIJEX AILCM AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC ASUFR BKOMP BOYCO BQLVK BS7 BYPQX C45 CGR CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2M F2N F5P FCALG FL- FRP FW0 GNXGY GQDEL H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JENOY JF9 JG8 JK3 JK8 JKPJF JPL JPM JST JVCUD K8S KD2 L-C L7B LMP NPM N~7 N~B N~M O9- OAG OAH OBH OCUKA ODA ODMTH OHH OHYEH OK1 OLB OLG OLH OLU OLY OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWU OWV OWW OWZ OXXIT P-K P2P PQQKQ R58 RIG RLZ RXW S4R S4S SA0 T8P TAE TAF TEORI TR2 TSPGW V2I VVN W2D W3M WH7 WOQ WOW X3V X3W XFW XXN XYM YFH YOC ZFV ZGI ZXP ZY1 ZZMQN 7X8 ADKSD ADSXY |
| ID | FETCH-LOGICAL-c5054-9eb01d6391ddf8e3bfb2c91ab8fafe35c75f622b52d011a8b79d4423d0679d072 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 17 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000388202400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-4521 |
| IngestDate | Mon Sep 08 15:41:12 EDT 2025 Mon Jul 21 05:36:17 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5054-9eb01d6391ddf8e3bfb2c91ab8fafe35c75f622b52d011a8b79d4423d0679d072 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 27835625 |
| PQID | 1839111833 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1839111833 pubmed_primary_27835625 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-December |
| PublicationDateYYYYMMDD | 2016-12-01 |
| PublicationDate_xml | – month: 12 year: 2016 text: 2016-December |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Sexually transmitted diseases |
| PublicationTitleAlternate | Sex Transm Dis |
| PublicationYear | 2016 |
| SSID | ssj0014801 |
| Score | 2.2584507 |
| Snippet | Our reverse syphilis testing algorithm consists of a treponemal IgG multiplex flow immunoassay (MFI) followed by both rapid plasma reagin titer and the... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 737 |
| SubjectTerms | Agglutination Tests Algorithms Antibodies, Bacterial - immunology Female Humans Immunoassay Male Retrospective Studies Sensitivity and Specificity Syphilis - diagnosis Syphilis - microbiology Syphilis Serodiagnosis - economics Treponema pallidum - immunology Treponema pallidum - isolation & purification |
| Title | Use of Treponemal Screening Assay Strength of Signal to Avoid Unnecessary Confirmatory Testing |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27835625 https://www.proquest.com/docview/1839111833 |
| Volume | 43 |
| WOSCitedRecordID | wos000388202400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvAa2jw3OUkRi4e2VtpCT4Z91hxMalML_ffO5EFPgmAOgcAmLLuz833Z2fmGkActADhcY1uATtzyGEreAspY2hGSt3XkCVPMdI8NBuF0Gg2rDbe8OlZZ-8TCUatM4h55C5Ec1mXouo_zLwurRmF0tSqhsU0aLlAZXJhsuokioDRKqZeK2t6OXafORaz12nsrpQvry8ec999IZgE23cP_dvOIHFQ0k3ZKuzgmWzo9IXv9KpB-St4nuaaZoWOMGaT6E9qOJB7BASSjMGV8TTFenc6WH9hslMzwc8uMdlZZougEvDPmF_DFmmLOYILEN4OHMYp2pLMzMuk-j59erKrUgiWBAnlWBHNmK2ArtlIm1K4wwpGRzUVouNGuL5lvAscRvqPAIfBQsEh5wMQU7kOpNnPOyU4K3b0kVHIPzML2JUCf58ogDDQ3wrQNs7kdMd0k9_XIxWDKGJ_gqc6-83gzdk1yUQ5_PC81N2IsCIL_ald_ePua7AOtCcpDJzekYWAh61uyK1fLJF_cFTYC98Gw_wML4cWv |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+Treponemal+Screening+Assay+Strength+of+Signal+to+Avoid+Unnecessary+Confirmatory+Testing&rft.jtitle=Sexually+transmitted+diseases&rft.au=Berry%2C+Gregory+J&rft.au=Loeffelholz%2C+Michael+J&rft.date=2016-12-01&rft.eissn=1537-4521&rft.volume=43&rft.issue=12&rft.spage=737&rft_id=info:doi/10.1097%2Folq.0000000000000524&rft_id=info%3Apmid%2F27835625&rft_id=info%3Apmid%2F27835625&rft.externalDocID=27835625 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-4521&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-4521&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-4521&client=summon |